Modified HCV E2 Glycoprotein Vaccine Design
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for hepatitis C virus (HCV) infection, particularly antiviral drug therapies, face challenges such as rapid viral load re-establishment, severe side effects, and low patient compliance due to frequent dosing requirements, and there is a lack of an effective vaccine to prevent or treat HCV infection.
Innovation Solution
A modified HCV E2 glycoprotein is developed, which includes deletions in the intergenotypic variable region (igVR) and hypervariable regions (HVR1 and HVR2), replaced with flexible linker sequences, to elicit antibodies that neutralize HCV and bind to the CD81 receptor, mimicking wild-type binding efficiency.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Productivity
If antiviral drug therapy (alpha-interferon and ribavirin) is used to treat HCV infection, then viral load decreases rapidly, but the viral load re-establishes rapidly after treatment stops and severe side effects occur
Solution Approach 1:
The patent applies preliminary action by developing a vaccine that prepares the immune system in advance to recognize and neutralize HCV. The vaccine introduces viral antigens (envelope glycoproteins E1 and E2) and regulatory elements before infection occurs, enabling the immune system to respond rapidly and effectively upon exposure, thereby preventing viral establishment rather than merely suppressing it temporarily like antiviral drugs do.
Solution Approach 2:
The patent uses an intermediary approach by employing a viral vector (adenovirus or retrovirus) as a delivery mechanism. This vector carries the HCV envelope glycoprotein genes and regulatory elements, serving as an intermediary that transfers genetic information into host cells to produce viral antigens, thereby stimulating immune response without requiring direct administration of antiviral drugs.
2Productivity
If alpha-interferon treatment is used for HCV infection, then viral load decreases, but frequent dosing is required due to rapid elimination from the body
Solution Approach 1:
The patent achieves continuity of useful action by designing a vaccine that provides long-lasting immune memory. Once the vaccine stimulates production of neutralizing antibodies and cytotoxic T cells, these immune components persist in the body for years, continuously protecting against HCV without requiring repeated dosing. The vaccine's regulatory elements ensure sustained expression of viral antigens during the immune response phase.
Solution Approach 2:
The patent applies self-service by enabling the patient's own immune system to produce and maintain protective antibodies and memory cells against HCV. The vaccine triggers the immune system to autonomously recognize viral antigens and mount a sustained response, eliminating the need for continuous external intervention through frequent dosing of antiviral medications.
3Productivity
If alpha-interferon and ribavirin combination therapy is used, then HCV levels decrease rapidly, but severe side effects including flu-like symptoms, bone marrow suppression, and depression occur
Solution Approach 1:
The patent converts the harmful effect of viral infection into a beneficial immune response. By introducing controlled amounts of viral antigens through the vaccine, the harmful HCV infection is transformed into a useful training exercise for the immune system, which then develops specific neutralizing antibodies and memory cells that protect against future infections without causing the severe side effects associated with antiviral drug therapy.
Solution Approach 2:
The patent uses copying by creating a simplified, safe version of the viral infection process. The vaccine contains genetic information that copies essential viral antigens (envelope glycoproteins) without replicating the full viral genome or causing active infection. This copying approach allows the immune system to study and respond to viral structures in a controlled manner, producing protective immunity without the harmful effects of actual viral replication or aggressive antiviral treatment.
4Ease of operation
If pegylated interferon is used to increase half-life and reduce dosing frequency, then patient compliance improves, but treatment efficacy is achieved in less than 50% of patients
Solution Approach 1:
The patent applies parameter changes by fundamentally altering the mechanism of action from pharmacological intervention to immunological activation. Instead of modifying the half-life of interferon to reduce dosing frequency, the vaccine changes the parameter of immune memory duration, which naturally persists for years. This parameter change in the biological system's response time eliminates the need for frequent dosing while achieving high efficacy through sustained immune recognition and neutralization capability.
Data Source
Figure 1A.i~1
Figure 2
Figure 3A~3B
AI summary
The invention provides modified hepatitis C virus (HCV) E2 glycoproteins comprising the HCV-E2 receptor-binding domain (RBD) including the HVR1, HVR2 and igVR variable regions wherein in at least one of said variable regions at least a part of the variable region is replaced with a flexible linker sequence. The invention also provides vaccine compositions comprising the modified glycoproteins as well as methods of use thereof.